Physician

Renjitha Tom Ignatius, M.D.

According to 2025 Medicare claims, Renjitha Ignatius, M.D. (NPI: 1417163999) practices hematology/oncology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33573-6825.

Ignatius' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,126 traditional Medicare patients, billed 535,905 HCPCS/CPT codes, and received $7,623,630 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 3,223 prescription claims across 601 beneficiaries totaling $7,991,367 in drug costs, led by Revlimid (Lenalidomide). DME data shows 41 claims. Open Payments data shows 198 records totaling $4,128. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $318,272 to $7,623,630. Similarly, Part D prescription costs have moved sharply higher in recent years, from $300,971 to $7,991,367. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	301	21,765	$318,272
2016	397	28,402	$200,144
2017	558	111,432	$953,219
2018	657	217,696	$1,841,947
2019	920	342,262	$3,341,487
2020	904	378,545	$4,673,920
2021	923	414,490	$5,691,399
2022	955	387,304	$4,587,701
2023	974	381,175	$5,244,196
2024	1,126	535,905	$7,623,630

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	127	514	$300,971
2016	56	133	$66,941
2017	90	321	$153,529
2018	155	1,003	$582,423
2019	221	1,306	$1,191,885
2020	277	1,481	$1,984,539
2021	358	1,527	$2,520,253
2022	337	1,425	$3,339,999
2023	396	1,744	$3,847,236
2024	601	3,223	$7,991,367

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	52	$3,868
2019	N/R	N/R	N/R
2020	N/R	62	$2,659
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	13	$213
2024	N/R	41	$914

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	292	401	$131
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	803	1,917	$94
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	793	1,613	$13
36415	Insertion of needle into vein for collection of blood sample	953	3,738	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	923	3,648	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	137	3,826	$2,261,446
Verzenio	Abemaciclib	54	1,512	$778,505
Pomalyst	Pomalidomide	26	728	$582,869
Jakafi	Ruxolitinib Phosphate	29	870	$489,019
Brukinsa	Zanubrutinib	26	780	$360,911

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	17	$494
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$213
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	198	$4,128	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Renjitha Tom Ignatius, M.D.?

Tedicare shows public-source Medicare data for Renjitha Tom Ignatius, M.D. (NPI 1417163999), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Renjitha Tom Ignatius, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Renjitha Tom Ignatius, M.D.?

Renjitha Tom Ignatius, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Renjitha Tom Ignatius, M.D. have Open Payments data?

Renjitha Tom Ignatius, M.D. has 198 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.